Recent Updates
Recently added Catalysts

histamine

Phase 3

Osteoarthritis of the Knee | Monoclonal antibody | Musculoskeletal |Apimeds Pharmaceuticals US, Inc.|Last Updated: Dec 13, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment363
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01112722Apitox, Honeybee Toxin for Pain and Inflammation of OsteoarthritisPHASE3 COMPLETED 363Dec 1, 2013Dec 1, 2016Dec 13, 201615 United States, United States +13
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
PurposeTREATMENT
Interventions
NameTypeDescription
Apitox, purified honeybee toxin, lyophilized in salineBIOLOGICALintradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
histamineBIOLOGICALimitates pain and erythema of honeybee venom
Unlock Study Design Details